Components:
Treatment option:
Medically reviewed by Fedorchenko Olga Valeryevna, PharmD. Last updated on 15.03.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Cinnarizin Actavise is used for the control of vestibular disorders such as vertigo, tinnitus, nausea and vomiting such as that seen in Meniere's disease.
Cinnarizin Actavise is also effective in the control of motion sickness.
Cinnarizin Actavis is for the control of vestibular disorders such as vertigo, tinnitus, nausea and vomiting such as is seen in Meniere's Disease.
Cinnarizin Actavis is also effective in the control of motion sickness.
Posology
Vestibular symptoms:
Adults, elderly and children over 12 years:
Two tablets three times a day.
Children 5-12 years:
One tablet three times a day.
The stated doses should not be exceeded.
Motion sickness:
Adults, elderly and children over 12 years:
Two tablets two hours before travel and one tablet every eight hours during journey if necessary.
Children 5-12 years:
One tablet two hours before travel and half a tablet every eight hours during journey if necessary.
Method of administration
For oral use.
Cinnarizin Actavise should preferably be taken after meals. The tablets may be sucked, chewed or swallowed whole with water.
Method of administration
Oral. The tablets may be chewed, sucked or swallowed whole.
Posology
Cinnarizin Actavis should preferably be taken after meals.
Vestibular symptoms
Adults, elderly and children over 12 years: 2 tablets three times a day.
Children 5 to 12 years: One half the adult dose.
These doses should not be exceeded.
Motion sickness
Adults, elderly and children over 12 years: 2 tablets 2 hours before you travel and 1 tablet every 8 hours during your journey.
Children 5 to 12 years: One half the adult dose.
Cinnarizin Actavis should not be given to patients with known hypersensitivity to cinnarizine.
As with other antihistamines, Cinnarizin Actavise may cause epigastric discomfort; taking it after meals may diminish gastric irritation. Cinnarizin Actavise should only be given to patients with Parkinson's disease if the advantages outweigh the possible risk of aggravating this disease.
Use of Cinnarizin Actavise should be avoided in porphyria.
There have been no specific studies in hepatic or renal dysfunction. Cinnarizin Actavise should be used with care in patients with hepatic or renal insufficiency.
Cinnarizin Actavise Tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
As with other antihistamines, Cinnarizin Actavis may cause epigastric discomfort; taking it after meals may diminish the gastric irritation.
In patients with Parkinson's Disease, Cinnarizin Actavis should only be given if the advantages outweigh the possible risk of aggravating this disease.
Because of its antihistamine effect, Cinnarizin Actavis may prevent an otherwise positive reaction to dermal reactivity indicators if used within 4 days prior to testing.
Use of cinnarizine should be avoided in porphyria.
There have been no specific studies in hepatic or renal dysfunction. Cinnarizin Actavis should be used with care in patients with hepatic or renal insufficiency.
Patients with rare hereditary problems of fructose or galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency, should not take this medicine because it contains lactose and sucrose.
Cinnarizin Actavise may cause drowsiness, especially at the start of treatment; patients affected in this way should not drive or operate machinery.
Cinnarizin Actavis may cause drowsiness, especially at the start of treatment; patients affected in this way should not drive or operate machinery.
The safety of Cinnarizin Actavise was evaluated in 372 Cinnarizin Actavise-treated subjects who participated in 7 placebo-controlled trials for the indications peripheral circulatory disorders, cerebral circulatory disorders, vertigo and seasickness; and in 668 Cinnarizin Actavise treated subjects who participated in six comparator and thirteen open label clinical trials for the indications peripheral circulatory disorders, cerebral circulatory disorders and vertigo. Based on pooled safety data from these clinical trials, the most commonly reported (>2% incidence) adverse drug reactions (ADRs) were: somnolence (8.3) and weight increased (2.1).
Including the above mentioned ADRs, the following ADRs have been observed from clinical trials and post-marketing experiences reported with the use of Cinnarizin Actavise. Frequencies displayed use the following convention:
Very common (> 1/10); common (> 1/100 to < 1/10); uncommon (> 1/1,000 to < 1/100); rare (> 1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data).
| System organ class | Adverse drug reactions | ||
| Frequency category | |||
| Common | Uncommon | Not known | |
| Nervous system disorders | Somnolence | Lethargy | Dyskinesia, extrapyramidal disorder (sometimes associated with depressive feelings), Parkinsonism, tremor |
| Gastrointestinal disorders | Nausea, dyspepsia | Vomiting, upper abdominal pain | |
| Hepatobiliary disorders | Cholestatic jaundice | ||
| Skin and subcutaneous tissue disorders | Hyperhidrolysis, Lichenoid keratosis including lichen planus | Subacute cutaneous lupus erythematosus | |
| Musculoskeletal and connective tissue disorders | Muscle rigidity | ||
| General disorders and administrative site conditions | Fatigue | ||
| Investigations | Weight increased | ||
Cases of hypersensitivity, headache and dry mouth have also been reported.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
The safety of Cinnarizin Actavis was evaluated in 372 cinnarizine-treated subjects who participated in 7 placebo-controlled trials for the indications peripheral circulatory disorders, cerebral circulatory disorders, vertigo and seasickness; and in 668 cinnarizine-treated subjects who participated in six comparator and thirteen open label clinical trials for the indications peripheral circulatory disorders, cerebral circulatory disorders and vertigo. Based on pooled safety data from these clinical trials, the most commonly reported (>2% incidence) Adverse Drug Reactions (ADRs) were: somnolence (8.3) and weight increased (2.1).
Including the above mentioned ADRs, the following ADRs have been observed from clinical trials and post-marketing experiences reported with the use of Cinnarizin Actavis. Frequencies displayed use the following convention:
Very common (> 1/10); common (> 1/100 to < 1/10); uncommon (> 1/1,000 to < 1/100); rare (> 1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
| System Organ Class | Adverse Drug Reactions | ||
| Frequency Category | |||
| Common (> 1/100 to < 1/10) | Uncommon (> 1/1,000 to < 1/100) | Not Known | |
| Nervous System Disorders | Somnolence | Lethargy | Dyskinesia; Extrapyramidal disorder; Parkinsonism; Tremor |
| Gastrointestinal Disorders | Nausea; Dyspepsia | Vomiting; Upper abdominal pain | |
| Hepato-biliary disorders | Cholestatic jaundice | ||
| Skin and subcutaneous tissue disorders | Hyperhydrosis; Lichenoid keratosis including lichen planus | Subacute cutaneous lupus erythematosus | |
| Musculoskeletal and Connective Tissue Disorders | Muscle rigidity | ||
| General Disorders and Administration Site Conditions | Fatigue | ||
| Investigations | Weight increased | ||
Cases of hypersensitivity, headache and dry mouth have been reported.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms
The signs and symptoms are mainly due to the anticholinergic (atropine-like) activity of Cinnarizin Actavise.
Acute Cinnarizin Actavise overdoses have been reported with doses ranging from 90 to 2,250 mg. Vomiting, alterations in consciousness ranging from somnolence to stupor and coma, extrapyramidal symptoms and hypotonia are the most commonly reported signs and symptoms associated with a Cinnarizin Actavise overdose. In a small number of young children, seizures developed. Clinical consequences were not severe in most cases, but deaths have been reported after single and polydrug overdoses involving Cinnarizin Actavise.
Treatment
There is no specific antidote to Cinnarizin Actavise and in the event of overdosage, treatment is symptomatic and supportive care. The administration of activated charcoal should only be considered in patients presenting within one hour of taking a potentially toxic overdose (i.e. more than 15 mg/kg).
Symptoms
The signs and symptoms are mainly due to the anticholinergic (atropine-like) activity of cinnarizine.
Acute cinnarizine overdoses have been reported with doses ranging from 90 to 2,250 mg. The most commonly reported signs and symptoms associated with overdose of cinnarizine include: alterations in consciousness ranging from somnolence to stupor and coma, vomiting, extrapyramidal symptoms, and hypotonia. In a small number of young children, seizures developed. Clinical consequences were not severe in most cases, but deaths have been reported after single and polydrug overdoses involving cinnarizine.
Treatment
There is no specific antidote. For any overdose, the treatment is symptomatic and supportive care.
It is advisable to contact a poison control center to obtain the latest recommendations for the management of an overdose.
Pharmacotherapeutic group: Antivertigo preparations, ATC code: N07CA02.
Mechanism of action
Cinnarizin Actavise is a piperazine derivative with the actions and uses of the antihistamines.
Cinnarizin Actavise has been shown to be a non-competitive antagonist of the smooth muscle contractions caused by various vasoactive agents including histamine. It acts on smooth muscle by selectively inhibiting the transport of calcium ions across cell membranes into depolarised cells, therefore reducing the availability of free Ca+ ions for the induction and maintenance of contraction.
Pharmacodynamic effects
Vestibular eye reflexes induced by caloric stimulation of the labyrinth in guinea pigs are markedly depressed by Cinnarizin Actavise.
Cinnarizin Actavise has been shown to inhibit nystagmus.
ATC Code N07CA02.
Cinnarizine has been shown to be a non-competitive antagonist of the smooth muscle contractions caused by various vasoactive agents including histamine.
Cinnarizine also acts on vascular smooth muscle by selectively inhibiting the calcium influx into depolarised cells, thereby reducing the availability of free Ca2+ ions for the induction and maintenance of contraction.
Vestibular eye reflexes induced by caloric stimulation of the labyrinth in guinea pigs are markedly depressed by cinnarizine.
Cinnarizine has been shown to inhibit nystagmus.
Absorption
In man, after oral administration, absorption is relatively slow, peak serum concentrations occurring after 2.5 to 4 hours.
Distribution
The plasma protein binding of Cinnarizin Actavise is 91%
Biotransformation
In animals, Cinnarizin Actavise is extensively metabolised, N-dealkylation being the major pathway.
Cinnarizin Actavise undergoes extensive metabolism mainly via CYP2D6 but there is considerable interindividual variation in the extent of metabolism.
Elimination
Approximately two thirds of the metabolites are excreted with the faeces, the rest in the urine (unchanged as metabolites and glucuronide conjugates), mainly during the first five days after a single dose.
The reported elimination half-life for Cinnarizin Actavise ranges from 4 to 24 hours.
In animals, cinnarizine is extensively metabolised, N-dealkylation being the major pathway. Approximately two thirds of the metabolites are excreted with the faeces, the rest in the urine, mainly during the first five days after a single dose.
Absorption
In man, after oral administration, absorption is relatively slow, peak serum concentrations occurring after 2.5 to 4 hours.
Distribution
The plasma protein binding of cinnarizine is 91%.
Metabolism
Cinnarizine is extensively metabolised mainly via CYP2D6, but there is considerable interindividual variation in the extent of metabolism.
Elimination
The reported elimination half-life for cinnarizine ranges from 4 to 24 hours.
The elimination of metabolites occurs as follows: one third in the urine (unchanged as metabolites and glucuronide conjugates) and two thirds in the faeces.
Nonclinical safety studies showed that effects were observed only after chronic exposures from approximately 7 to 35 times the recommended maximum daily human dose of 90 mg/day calculated on a body surface area basis. Cinnarizin Actavise blocked the cardiac hERG channel in vitro, however in isolated cardiac tissue and following intravenous application in guinea-pigs, no QTc prolongation or proarrhythmic effects were observed at substantially higher exposures than those expected clinically.
In reproductive studies in the rat, rabbit, and dog, there was no evidence of adverse effects on fertility and no teratogenicity. At high doses associated with maternal toxicity in the rat there was a decreased litter size, an increase in resorptions and a decrease in foetal birth weight.
In vitro mutagenicity studies indicated that the parent compound is not mutagenic however, after reacting with nitrite and forming the nitrosation product, a weak mutagenic activity was observed. Carcinogenicity studies have not been conducted however, no pre-neoplastic changes were evident during chronic 18-month oral administration in rats up to approximately 35 times the maximum human dose level.
Nonclinical safety studies showed that effects were observed only after chronic exposures from approximately 7 to 35 times the recommended maximum daily human dose of 90 mg/day calculated on a body surface area basis. Cinnarizine blocked the cardiac hERG channel in vitro, however in isolated cardiac tissue and following intravenous application in guinea-pigs, no QTc prolongation or proarrhythmic effects were observed at substantially higher exposures than those expected clinically.
In reproductive studies in the rat, rabbit, and dog, there was no evidence of adverse effects on fertility and no teratogenicity. At high doses associated with maternal toxicity in the rat there was a decreased litter size, an increase in resorptions and a decrease in fetal birth weight.
In vitro mutagenicity studies indicated that the parent compound is not mutagenic however, after reacting with nitrite and forming the nitrosation product, a weak mutagenic activity was observed. Carcinogenicity studies have not been conducted however, no pre-neoplastic changes were evident during chronic 18-month oral administration in rats up to approximately 35 times the maximum human dose level.
Not applicable
None known.
No special requirements
No special requirements.
